The observation that salsalate and diflunisal decrease both AD and TBI incidence suggests these drugs may prevent injury occurrence, not just treat consequences. This unexpected finding challenges the assumed mechanism of action and has major therapeutic implications. Gap type: unexplained_observation Source paper: Reducing acetylated tau is neuroprotective in brain injury. (2021, Cell, PMID:33852912)
Landscape Summary: Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI in human patients? is a 0.89 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI in human patients? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: